Abstract
Nicotinic acetylcholine receptors (nAChRs) exist as a diverse family of physiologically important ligand-gated ion channels active in classic, excitatory neurotransmission and perhaps in more novel forms of neurochemical signaling. Because of their critical functional roles centrally and peripherally, nAChRs are ideal targets for the regulation of nervous system function. nAChRs also are targets of nicotine, which acts acutely like acetylcholine to stimulate nAChR function. Here, we report studies using model cell culture systems testing the general hypothesis that more chronic nicotine exposure has unique effects on nAChRs. Chronic nicotine treatment induces increases in numbers of human muscle-type nAChRs containing alpha-1,beta-1, gamma and deltasubunits, a human ganglionic nAChR subtype containingalpha-3 and beta-4 subunits and a human ganglionic nAChR containing alpha-7 subunits in intracellular and (except for alpha-7 nAChRs) in cell surface pools. However, the half-maximal potency with which nicotine has these effects differs across these nAChR subtypes, as do rates and magnitudes of the “nicotine-induced nAChR up-regulation.” These changes in nAChR numbers are not attributable to either transient or sustained changes in nAChR subunit mRNA levels. Nicotine exposure more potently, more rapidly, and with nAChR-subtype specificity, induces two phases of losses in functional responsiveness of muscle-type nAChRs andalpha-3 beta-4 nAChRs, including a “persistent inactivation” that is distinct from classicly defined “desensitization.” Based on these results, we hypothesize that chronic nicotine treatment induces persistent functional inactivation and numerical up-regulation of all nAChR subtypes viadistinct post-transcriptional mechanisms and with potencies, at rates and with magnitudes that are nAChR-subtype specific. We also hypothesize that chronic nicotine exposure produces long-lasting changes in nervous system function, at least in part, by disabling rather than activating nicotinic cholinergic signaling.
Footnotes
-
Send reprint requests to: Dr. Ronald J. Lukas, Division of Neurobiology, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, Arizona 85013. E-mail:rlukas{at}mha.chw.edu
-
↵1 Work toward this project was supported by endowment and capitalization funds from the Men’s and Women’s Boards of the Barrow Neurological Foundation and Epi-Hab Phoenix and by grants from the Arizona Disease Control Research Commission (82–1-098 and 9730), the Smokeless Tobacco Research Council (0277–01) and the National Institute on Drug Abuse (DA07319). The contents of this report are solely the responsibility of the authors and do not necessarily represent the views of the aforementioned awarding agencies.
-
↵2 Present address: Research and Development, R.J. Reynolds Tobacco, Winston-Salem, NC 27102.
- Abbreviations:
- ACh
- acetylcholine
- Carb
- carbamylcholine
- DMEM
- Dulbecco’s modified Eagle’s medium
- I-Bgt
- 125I-labeled α-bungarotoxin
- nAChR
- nicotinic acetylcholine receptor
- Received January 22, 1998.
- Accepted April 10, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|